Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Status Not yet recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of ABCD in the treatment of cryptococcal meningitis in non-HIV patients at week 4, the end of induction therapy, week 10 and the end of consolidation therapy.

Clinical Trial Description

This study is a multi-center, single-arm clinical study. The objective is to evaluate the efficacy and safety of ABCD in the treatment of cryptococcal meningitis in non-HIV patients. Qualified subjects shall receive cryptococcus induction therapy with ABCD combined with flucytosine for at least 4 weeks, or termination of treatment early at the investigator's discretion. Efficacy and safety are followed up at week 4 (day 28), the end of induction therapy, week 10 (day 70) and the end of consolidation therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05471063
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Wei Cao, PhD
Phone	010-69156114
Email	wcao_pumch@163.com
Status	Not yet recruiting
Phase	N/A
Start date	August 22, 2022
Completion date	April 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01589289` - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC	Phase 3
Completed	`NCT00976040` - Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis	Phase 4
Completed	`NCT04031833` - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)	Phase 1/Phase 2
Completed	`NCT00830856` - Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa	N/A
Completed	`NCT04532463` - Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
Completed	`NCT02098525` - Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy	N/A
Completed	`NCT01075152` - Cryptococcal Optimal ART Timing Trial	Phase 4
Active, not recruiting	`NCT01715922` - Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa	Phase 2/Phase 3
Completed	`NCT00145249` - Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis	Phase 2
Completed	`NCT01802385` - Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis	Phase 3
Terminated	`NCT00324025` - Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS	Phase 2
Completed	`NCT02955862` - Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report	Phase 1
Recruiting	`NCT03945448` - Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia	Phase 2/Phase 3
Active, not recruiting	`NCT02624453` - Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS	N/A
Recruiting	`NCT00867269` - Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Completed	`NCT01535469` - Operational Research for Cryptococcal Antigen Screening	Phase 4
Active, not recruiting	`NCT04072640` - Three Induction Treatments on Cryptococcal Meningitis	Early Phase 1
Not yet recruiting	`NCT05541107` - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3	Phase 3
Not yet recruiting	`NCT02686853` - Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis	Phase 4
Not yet recruiting	`NCT04140461` - AmB Dose for Cryptococcal Meningitis	Phase 3